Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa first-in-human study of DB-1419 in advanced or metastatic solid tumors
CTR20251125Phase 2Active
- Sponsor
- Duality Biotherapeutics
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DB-1419 in Nonhematologic neoplasms, sponsored by Duality Biotherapeutics. Started May 2025; status: active.
02
Drugs
DB-1419
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251125.